|
Welcome
|
|
13 October 2008
|
|
|
| home | my details | ISRCTN Register | mRCT | UKCTG | links | information | news |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
| [ ...Back to search results ] | [ Print-friendly version ] |
| Can monitoring exhaled nitric oxide levels in outpatients improve the management of children with asthma? |
| Source of record | UK Clinical Trials Gateway |
| ISRCTN | ISRCTN50872816 |
| Date ISRCTN assigned | 31/07/2007 |
| Local reference number(s) | 4 |
| Public title | Can monitoring exhaled nitric oxide levels in outpatients improve the management of children with asthma? |
| Scientific title | |
| Acronym | Exhaled nitric oxide study |
| Disease/condition/study domain | Asthma |
| Study hypothesis | The aim of this study is to explore whether monitoring exhaled Nitric Oxide (eNO) levels in outpatients improves the management of children with asthma using a pragmatic experimental design. The specific objectives are: 1. To determine whether using eNO levels in outpatients to direct therapy allows less inhaled corticosteroid to be used over a year of follow when compared to a control group 2. To determine whether using eNO levels in outpatients to direct therapy reduces the number of exacerbations that require treatment with systemic corticosteroid over a year of follow when compared to a control group |
| Design/methodology | A multicentre, pragmatic, prospective, randomised, double-blind, study |
| Research ethics review | Southampton and Southwest Hampshire Local Research Ethics Committee approved on 18th May 2006 (ref: 06/Q1702/9). |
| Countries of trial | United Kingdom |
| Participants - inclusion criteria | 1. Aged 6 - 17 years 2. Clinical diagnosis of asthma 3. Treatment with at least 400 mcg daily of beclomethasone/budesonide or 200 mcg daily of fluticasone |
| Participants - exclusion criteria | 1. Inability to perform lung function or eNO measurement 2. Cigarette smoking 3. Poor compliance with medication 4. Previous life-threatening exacerbations 5. Need for maintenance oral prednisolone |
| Patient information material | |
| Anticipated start date | 12/12/2006 |
| Anticipated end date | 31/08/2008 |
| Status of trial | Ongoing |
| Target number of participants | 150 |
| Interventions | 150 subjects aged 6 to 17 years with moderate or severe asthma will be recruited. Their asthma will be stabilised and they will be randomised to the exhaled nitric oxide (eNO) or control group. All will be assessed every two months for a year. The control group will be managed according to the British Thoracic Society guidelines. In the eNO group, the inhaled corticosteroid doses will be increased in response to elevated eNO levels and reduced if levels are low. Subjects and medical staff involved in managing any exacerbations will be blind to group allocation. An intention to treat analysis will be undertaken with a comparison of the change in inhaled corticosteroid dose and the number of exacerbations over the one-year follow up period between the two groups. It is expected that the eNO group will use less inhaled corticosteroids and experience less exacerbations. |
| Primary outcome measure(s) | An intention to treat analysis will be undertaken with a comparison of the change in inhaled steroid dose and the number of exacerbations over the one-year follow up period between the eNO and control groups. |
| Secondary outcome measure(s) | 1. A per protocol analysis will be undertaken, the dataset for this analysis will be restricted to the subjects whose therapy was directed as per the protocol 2. Subgroup analysis restricted to subjects taking inhaled corticosteroid through a metered dose inhaler with a spacer as it is expected that these will form a more homogeneous analysis group 3. Subgroup analysis focusing firstly on subjects with moderate (400 - 800 mcg/day beclomethasone equivalent) and secondly subjects with severe (greater than 800 mcg/day beclomethasone equivalent) asthma to determine whether results are similar in both groups 4. Subgroup analysis focusing on firstly on atopic asthmatics and secondly non-atopic ones 5. Analyses restricted firstly to only viral associated exacerbations and secondly to exacerbations that are not associated with a viral infection 6. Comparison of the average inhaled steroid use in each group over the last six months of follow up |
| Sources of funding | Sport Aiding Medical Research for Kids (SPARKS) (UK) |
| Sponsor name | University of Southampton (UK) |
| Sponsor details | Research Governance Legal Services Building 37 Highfield Road Southampton United Kingdom SO17 1BJ |
| Sponsor website | http://www.soton.ac.uk/ |
| Contact name | Dr Graham Roberts |
| Contact details | Clinical Senior Lecturer/Consultant Paediatrician University Child Health (MP803) Level F South Academic Block Southampton University Hospital NHS Trust Tremona Road Southampton United Kingdom SO16 6YD |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN50872816 |
| Date last extracted from ISRCTN register | 17/04/2008 |
|
|
|
| terms & conditions | privacy statement | © Current Controlled Trials Ltd | |
|
|
|
|